Leadless cardiac pacing devices including tissue engagement verification

ABSTRACT

An implantable leadless cardiac pacing device including a housing having a proximal end and a distal end, an electrode positioned proximate the distal end of the housing configured to be positioned adjacent cardiac tissue, and a tissue anchoring member extending from the distal end of the housing configured to secure the housing to cardiac tissue. The device further includes a tissue engagement verification feature configured to provide feedback upon engagement of the tissue anchoring member in cardiac tissue.

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation application of U.S. patentapplication Ser. No. 14/698,537, filed Apr. 28, 2015, which claims thebenefit of U.S. Provisional Application Ser. No. 61/985,826, filed Apr.29, 2014, the disclosures of which are incorporated herein in theirentirety.

TECHNICAL FIELD

The present disclosure pertains to medical devices, and methods formanufacturing medical devices. More particularly, the present disclosurepertains to leadless cardiac pacing devices including tissue engagementverification features.

BACKGROUND

Cardiac pacemakers provide electrical stimulation to heart tissue tocause the heart to contract and thus pump blood through the vascularsystem. Conventional pacemakers typically include an electrical leadthat extends from a pulse generator implanted subcutaneously orsub-muscularly to an electrode positioned adjacent the inside or outsidewall of the cardiac chamber. As an alternative to conventionalpacemakers, self-contained or leadless cardiac pacemakers have beenproposed. Leadless cardiac pacemakers are small capsules typicallyincluding bipolar pacing/sensing electrodes, a power source (e.g. abattery), and associated electrical circuitry for controlling thepacing/sensing electrodes, and thus provide electrical stimulation toheart tissue and/or sense a physiological condition. The small capsuleis typically fixed to an intracardiac implant site in a cardiac chamberwith a fixation mechanism engaging the intracardiac tissue.

Accordingly, it is desirable to provide alternative structures tofacilitate verification of sufficient engagement of the fixationmechanism into the intracardiac tissue to ensure the leadless cardiacpacemaker is secured to the intracardiac tissue.

SUMMARY

The disclosure is directed to several alternative designs, materials andmethods of manufacturing medical device structures and assemblies, anduses thereof.

Accordingly one illustrative embodiment is an implantable leadlesscardiac pacing device including a housing having a proximal end and adistal end, an electrode positioned proximate the distal end of thehousing configured to be positioned adjacent cardiac tissue, and atissue anchoring member extending from the distal end of the housingconfigured to secure the housing to cardiac tissue. The device furtherincludes a tissue engagement verification feature configured to providefeedback upon engagement of the tissue anchoring member in cardiactissue.

Another illustrative embodiment is an implantable leadless cardiacpacing device including a housing having a proximal end and a distalend, an electrode positioned proximate the distal end of the housingconfigured to be positioned adjacent cardiac tissue, and a tissueanchoring member extending from the distal end of the housing configuredto secure the housing to cardiac tissue. The device further includes aradiopaque marker movable relative to the housing and a radiopaquereference point stationary relative to the housing. Displacement of theradiopaque marker relative to the radiopaque reference point providesvisual feedback of engagement of the tissue anchoring member in cardiactissue.

Yet another illustrative embodiment is a method of implanting a leadlesscardiac pacing device. The method includes advancing the leadlesscardiac pacing device into a chamber of a heart. A tissue anchoringmember of the leadless cardiac pacing device is then engaged intocardiac tissue. While engaging the tissue anchor member into the cardiactissue, displacement of a radiopaque marker of the leadless cardiacpacing device relative to a radiopaque reference point isfluoroscopically observed to confirm engagement of the tissue anchoringmember in cardiac tissue.

The above summary of some example embodiments is not intended todescribe each disclosed embodiment or every implementation of theaspects of the disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

The disclosure may be more completely understood in consideration of thefollowing detailed description in connection with the accompanyingdrawings, in which:

FIG. 1 is a plan view of an exemplary leadless pacing device implantedwithin a heart;

FIG. 2 is a side view of an exemplary leadless pacing device;

FIG. 2A is a distal end view of the leadless pacing device shown in FIG.2;

FIG. 2B is a proximal end view of the leadless pacing device shown inFIG. 2;

FIGS. 3A-3C illustrate aspects of an exemplary method of implanting theleadless pacing device shown in FIG. 2 into cardiac tissue using adelivery catheter;

FIG. 4A is a side view of another exemplary leadless pacing device;

FIG. 4B is a distal end view of the leadless pacing device shown in FIG.4A;

FIGS. 5A-5B illustrate aspects of an exemplary method of implanting theleadless pacing device shown in FIG. 4A into cardiac tissue using adelivery catheter;

FIG. 6A is a side view of another exemplary leadless pacing device;

FIG. 6B is a distal end view of the leadless pacing device shown in FIG.6A;

FIGS. 7A-7B illustrate aspects of an exemplary method of implanting theleadless pacing device shown in FIG. 6A into cardiac tissue using adelivery catheter;

FIG. 8 is a side view of another exemplary leadless pacing device; and

FIGS. 9A-9B illustrate aspects of an exemplary method of implanting theleadless pacing device shown in FIG. 8 into cardiac tissue using adelivery catheter.

While the disclosure is amenable to various modifications andalternative forms, specifics thereof have been shown by way of examplein the drawings and will be described in detail. It should beunderstood, however, that the intention is not to limit the invention tothe particular embodiments described. On the contrary, the intention isto cover all modifications, equivalents, and alternatives falling withinthe spirit and scope of the disclosure.

DETAILED DESCRIPTION

For the following defined terms, these definitions shall be applied,unless a different definition is given in the claims or elsewhere inthis specification.

All numeric values are herein assumed to be modified by the term“about,” whether or not explicitly indicated. The term “about” generallyrefers to a range of numbers that one of skill in the art would considerequivalent to the recited value (i.e., having the same function orresult). In many instances, the terms “about” may include numbers thatare rounded to the nearest significant figure.

The recitation of numerical ranges by endpoints includes all numberswithin that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and5).

As used in this specification and the appended claims, the singularforms “a”, “an”, and “the” include plural referents unless the contentclearly dictates otherwise. As used in this specification and theappended claims, the term “or” is generally employed in its senseincluding “and/or” unless the content clearly dictates otherwise.

It is noted that references in the specification to “an embodiment”,“some embodiments”, “other embodiments”, etc., indicate that theembodiment described may include one or more particular features,structures, and/or characteristics. However, such recitations do notnecessarily mean that all embodiments include the particular features,structures, and/or characteristics. Additionally, when particularfeatures, structures, and/or characteristics are described in connectionwith one embodiment, it should be understood that such features,structures, and/or characteristics may also be used connection withother embodiments whether or not explicitly described unless clearlystated to the contrary.

The following detailed description should be read with reference to thedrawings in which similar elements in different drawings are numberedthe same. The drawings, which are not necessarily to scale, depictillustrative embodiments and are not intended to limit the scope of theinvention.

Cardiac pacemakers provide electrical stimulation to heart tissue tocause the heart to contract and thus pump blood through the vascularsystem. Conventional pacemakers typically include an electrical leadthat extends from a pulse generator implanted subcutaneously orsub-muscularly to an electrode positioned adjacent the inside or outsidewall of the cardiac chamber. As an alternative to conventionalpacemakers, self-contained or leadless cardiac pacemakers have beenproposed. A leadless cardiac pacemaker may take the form of a relativelysmall capsule that may be fixed to an intracardiac implant site in acardiac chamber. It can be readily appreciated that the implantation ofa leadless pacing device within a beating heart can be difficult.Accordingly, it may be desirable for a leadless pacing device to includea tissue engagement verification feature to facilitate verification ofsufficient engagement of the fixation mechanism into the intracardiactissue to ensure the leadless cardiac pacemaker is secured to theintracardiac tissue.

FIG. 1 illustrates an example implantable leadless cardiac pacing device10 implanted in a chamber of a heart H such as, for example, the rightventricle RV. The device 10 may include a shell or housing 12 having adistal region 14 and a proximal region 16. One or more anchoring members18 may be disposed adjacent to the distal region 14. The anchoringmember 18 may be used to attach the device 10 to a tissue wall of theheart H, such as intracardiac tissue, or otherwise anchor theimplantable device 10 to the anatomy of the patient. A docking member 20may be disposed adjacent to the proximal region 16 of the housing 12.The docking member 20 may be utilized to facilitate delivery and/orretrieval of the implantable device 10.

Some of the features of the device 10 can be seen in FIG. 2, FIG. 2A,and FIG. 2B. For example, the device 10 may include a first electrode 26positioned adjacent to the distal region 14 of the housing 12. A secondelectrode 28 may also be defined along the housing 12. For example, thehousing 12 may include a conductive material and may be insulated alonga portion of its length. A section along the proximal region 16 may befree of insulation so as to define the second electrode 28. Theelectrodes 26/28 may be sensing and/or pacing electrodes to provideelectro-therapy and/or sensing capabilities. The first electrode 26 maybe capable of being positioned against or otherwise contact the cardiactissue of the heart H while the second electrode 28 may be spaced awayfrom the first electrode 26, and thus spaced away from the cardiactissue. The device 10 may also include a pulse generator (e.g.,electrical circuitry) and a power source (e.g., a battery) within thehousing 12 to provide electrical signals to the electrodes 26/28.Electrical communication between the pulse generator and the electrodes26/28 may provide electrical stimulation to heart tissue and/or sense aphysiological condition.

The docking member 20 may include a head portion 22 and a neck portion24 extending between the housing 12 and the head portion 22. The headportion 22 may be capable of engaging with a delivery and/or retrievalcatheter. For example, the head portion 22 may include a bore or opening30 formed therein. The ends of the bore 30 may be open or exposed whilea central region of the bore 30 may be covered by a section the 34 ofthe head portion 22, for example. During delivery, the device 10 may besecured to a delivery device by extending a suture through the bore 30.Additionally or alternatively, a portion of the delivery catheter mayinclude projections or lugs that may engage the bore 30. Some additionaldetails of example delivery devices for delivering the device 10 tocardiac tissue are disclosed herein.

The docking member 20 may also be engaged if it is desired to retrieveand/or reposition the device 10. For example, a retrieval catheter maybe advanced to a position adjacent to the device 10. A retrievalmechanism such as a snare, tether, arm, or other suitable structure mayextend from the retrieval catheter and engage the head portion 22. Whensuitably engaged, the device 10 may be pulled from the cardiac tissueand, ultimately, removed from the patient or repositioned.

As the name suggests, the anchoring member 18 may be used to anchor thedevice 10 to the target tissue. A suitable number of anchoring members18 may be used with the device 10. For example, the device 10 mayinclude one, two, three, four, five, six, seven, eight, or moreanchoring members. In at least some embodiments, the anchoring member 18may take the form of a helix or screw. According to these embodiments,the anchoring member 18 may be threaded or rotated into cardiac tissue.In other instances, the anchoring member 18 may include one or more, ora plurality of tines configured to be anchored into the cardiac tissue.Some additional details of example mechanisms for threading/anchoringthe device 10 to cardiac tissue are disclosed herein.

It can be appreciated that in order to securely anchor the device 10 tocardiac tissue with a helical anchoring member 18 or other anchoringmember, it may be desirable to provide intraoperative verification ofsufficient engagement of the anchoring member 18 into the cardiac tissueto ensure the device 10 is secured to the cardiac tissue. Accordingly,the device 10 may include one or more tissue engagement verificationfeatures to provide the medical personnel intraoperative verification ofthe degree of tissue engagement of the anchoring member 18 during theimplantation procedure. Thus, the tissue engagement verification featuremay be configured to provide feedback upon engagement of the tissueanchoring member 18 in cardiac tissue. In some embodiments, the tissueengagement verification feature may be movable from a first positionrelative to the housing 12 to a second position relative to the housing12. In some instances, the first position may be an equilibriumposition, and the second position may be a displaced position throughapplication of an external force, such as through contact with thecardiac tissue. In some embodiments, the tissue engagement verificationfeature may be arranged with the device 10 such that the tissueengagement verification feature moves toward the proximal end of thehousing 12 as the tissue engagement verification feature moves from thefirst position to the second position. The tissue engagementverification feature may include a radiopaque material to provideintraoperative visual feedback via fluoroscopy during implantation ofthe device 10 in the heart H. The radiopaque material of the tissueengagement verification feature may be movable relative to the housing12, such that the movement of the tissue engagement verification featuremay be viewed using fluoroscopy during the medical procedure. In someembodiments, the device 10 may include a radiopaque reference pointwhich is stationary relative to the housing 12, such that displacementof the radiopaque material of the tissue engagement verification featurerelative to the radiopaque reference point provides visual feedback ofengagement of the tissue anchoring member 18 in cardiac tissue.

One exemplary example of tissue engagement verification features whichcan be included with the device 10 are illustrated in FIG. 2, FIG. 2Aand FIG. 2B. Tissue engagement verification features 50 may be fixedlyattached to the housing 12 of the device 10. In other words, the tissueengagement verification features 50 may be designed so that duringtypical use, the tissue engagement verification features 50 remainattached to housing 12. In some embodiments, the tissue engagementverification features 50 may have some freedom of movement relative tothe housing 10. For example, the tissue engagement verification features50 may be capable of pivoting, rotating, or otherwise moving relative tohousing 12.

The form of the tissue engagement verification features 50 may vary. Forexample, the tissue engagement verification features 50 may take theform of tines 32 projecting from housing 12. In some instances, thetines 32 may be symmetrically or asymmetrically arranged around theperimeter of the housing 12 and extend radially outward therefrom. Thetines 32 may extend radially from the housing 12 in a distal directionin a first, equilibrium position, shown in FIG. 2.

The tines 32 may be doped with, made of, or otherwise include aradiopaque material. In some instances, the tines 32 may include aradiopaque marker 40, such as at a distal tip of the tines 32, or alonganother portion of the tines 32. In other instances, the tines 32, or aportion thereof, may be formed of a radiopaque material or be doped witha radiopaque material, and thus serve as the radiopaque marker.Radiopaque materials are understood to be materials capable of producinga relatively bright image on a fluoroscopy screen or another imagingtechnique during a medical procedure. This relatively bright image aidsthe user of the device 10 visualizing the radiopaque marker (e.g., thetine 32) using fluoroscopy. Some examples of radiopaque materials caninclude, but are not limited to, gold, platinum, palladium, tantalum,tungsten alloy, polymer material loaded with a radiopaque filler, andthe like.

In some instances, the device 10 may also include a radiopaque referencepoint 60 which is stationary relative to the housing 12, or be includedas part of the housing 12. For example the radiopaque reference point 60may be a radiopaque ring surrounding the housing 12, or anotherradiopaque structure on the housing 12, or the material forming thehousing 12. Accordingly, displacement of the radiopaque material of thetines 32 relative to the radiopaque reference point 60 may providevisual feedback of engagement of the tissue anchoring member 18 incardiac tissue.

The tines 32 may have any desired cross-sectional shape, such as agenerally circular cross-sectional shape. In at least some embodiments,the tines 32 may be substantially straight. In other embodiments, thetines 32 may include one or more curves or bends. A variety of othershapes, forms, and configurations are also contemplated for the tines32. In addition, some devices may include combinations of differentlyshaped or oriented tines 32.

FIGS. 3A-3C illustrate aspects of an exemplary method of implanting theleadless pacing device shown in FIG. 2 into cardiac tissue using adelivery catheter 100. The catheter 100 may include a proximal member orregion 134 and a distal member or holding section 136 configured tohouse the implantable device 10 during a delivery procedure. A pushmember 138 may be disposed (e.g., slidably disposed) within the proximalregion 134. A distal or head region 139 of the push member 138 may bedisposed within the distal holding section 136. The head region 139 maybe capable of engaging the docking member 20 of the device 10. Forexample, the head region 139 may include one or more lugs 140 that arecapable of engaging the bore 30 formed in the docking member 20. Whenthe lugs 140 are engaged with the bore 30, the push member 138 may berotated to thread or rotate the anchor member 18 into a target region 90(e.g., a region of the heart such as the right ventricle). In someembodiments, a holding member or suture 144 may also extend through alumen formed in the push member 138 and pass through the bore 30 so asto secure the device 10 to the delivery catheter 100 during portions orall of the delivery process.

The catheter 100 may be advanced through the vasculature to targetregion 90, with the device 10 positioned in the distal holding section136 of the delivery catheter 100. For example, the catheter 100 may beadvanced through a femoral vein, into the inferior vena cava, into theright atrium, through the tricuspid valve, and into the right ventricle.The target region 90 may be a portion of the right ventricle. Forexample, the target region 90 may be a portion of the right ventriclenear the apex of the heart. In other instances, however, the targetregion 90 may be in another portion of the heart, such as in anotherchamber of the heart, for example.

The device 10 may include the anchor member 18 and tissue engagementverification features, such as the tines 32. During advancement of thecatheter 100 through the vasculature, the tines 32 may be oriented inthe distal direction (e.g., toward the distal end of the device 10and/or distally from the device 10).

When the device 10 has been positioned proximate the target region 90,the device 10 may be expelled from the distal holding section 136, asshown in FIG. 3B. For example, the device 10 may be rotated with thepush member 138 such that the anchoring member 18 screws into the targetregion 90 of cardiac tissue. As the anchoring member 18 is screwed intothe target region 90, the distal ends of the tines 32 may engage thetarget tissue 90. Further rotation or screwing of the anchoring memberinto the target tissue 90 may cause the tines 32 to move (e.g., deflect)from the first position, shown in FIG. 3B to a second position, shown inFIG. 3C. As the tines 32 move (e.g., deflect) via engagement with thecardiac tissue 90, the free ends of the tines 32 may move toward theproximal end of the housing 12 as the tines 32 move from the firstposition to the second position. Visual observation of the movement ofthe radiopaque material, such as the radiopaque markers 40, of the tines32 may provide intraoperative visual feedback via fluoroscopy duringimplantation of anchoring member 18 of the device 10 into the targetregion 90. In instances in which the device 10 includes a radiopaquereference point 60 which is stationary relative to the housing 12,displacement of the radiopaque material 40 of the tines 32 relative tothe radiopaque reference point 60 may provide visual feedback ofengagement of the tissue anchoring member 18 in the cardiac tissue 90.For example, medical personnel may confirm that the tissue anchoringmember 18 is sufficiently anchored in the cardiac tissue 90 when theradiopaque material (e.g., radiopaque marker 40) of the tines 32 movesto a predetermined distance from the radiopaque reference point 60 atthe second position. The predetermined distance may be less than thedistance from the radiopaque reference point 60 at the first position.

FIGS. 4A and 4B illustrate another illustrative example of a tissueengagement verification feature 150 incorporated with the implantableleadless cardiac pacing device 10. Tissue engagement verificationfeatures 150 may be fixedly attached to the housing 12 of the device 10.In other words, the tissue engagement verification features 150 may bedesigned so that during typical use, the tissue engagement verificationfeatures 150 remain attached to housing 12. In some embodiments, thetissue engagement verification features 150 may have some freedom ofmovement relative to the housing 10. For example, the tissue engagementverification features 150 may be capable of pivoting, rotating, orotherwise moving relative to housing 12.

The form of the tissue engagement verification features 150 may vary.For example, the tissue engagement verification features 150 may takethe form of a compressible member, such as an open wound coil 132. Theopen wound coil 132 is shown coaxial with the helical tissue anchoringmember 18, with the open wound coil 132 surrounding the tissue anchoringmember 18. However, in other embodiments, the open wound coil 132 may bepositioned within the helical tissue anchoring member 18, or otherwisedisposed. The open wound coil 132 may extend distally from the distalend of the housing 12, for example.

The open wound coil 132 may be constructed such that adjacent windingsof the open wound coil 132 are spaced apart a first distance when in afirst, uncompressed position, and move closer together with an appliedforce (e.g., a second, compressed position), such as upon engagement ofthe open wound coil 132 with cardiac tissue.

The open wound coil 132 may be doped with, made of, or otherwise includea radiopaque material. In some instances, only a discrete portion of theopen wound coil 132 may include a radiopaque material, such as at adistal tip of the open wound coil 132, or along another portion of theopen wound coil 132, and thus serve as a radiopaque marker. In otherinstances, the entire open wound coil 132 may be formed of a radiopaquematerial or be doped with a radiopaque material, and thus serve as aradiopaque marker. Radiopaque materials are understood to be materialscapable of producing a relatively bright image on a fluoroscopy screenor another imaging technique during a medical procedure. This relativelybright image aids the user of the device 10 visualizing the radiopaqueopen wound coil 132 using fluoroscopy. Some examples of radiopaquematerials can include, but are not limited to, gold, platinum,palladium, tantalum, tungsten alloy, polymer material loaded with aradiopaque filler, and the like.

In some instances, the device 10 may also include a radiopaque referencepoint which is stationary relative to the housing 12, or be included aspart of the housing 12. Accordingly, displacement of the radiopaque openwound coil 132 relative to the radiopaque reference point of the housing12 (e.g., compression of the open wound coil 132) may provide visualfeedback of engagement of the tissue anchoring member 18 in cardiactissue.

FIGS. 5A and 5B illustrate aspects of an exemplary method of implantingthe leadless pacing device shown in FIGS. 4A and 4B into cardiac tissueusing the delivery catheter 100. The delivery catheter 100, previouslydescribed above, may include a distal member or holding section 136configured to house the implantable device 10 during a deliveryprocedure. Additional features of the delivery catheter 100 have beendescribed above.

The catheter 100 may be advanced through the vasculature to targetregion 90, with the device 10 positioned in the distal holding section136 of the delivery catheter 100. For example, the catheter 100 may beadvanced through a femoral vein, into the inferior vena cava, into theright atrium, through the tricuspid valve, and into the right ventricle.The target region 90 may be a portion of the right ventricle. Forexample, the target region 90 may be a portion of the right ventriclenear the apex of the heart. In other instances, however, the targetregion 90 may be in another portion of the heart, such as in anotherchamber of the heart, for example.

The device 10 may include the anchor member 18 and tissue engagementverification features, such as the open wound coil 132. Duringadvancement of the catheter 100 through the vasculature, the open woundcoil 132, which may extend distally from the distal end of the housing12, may be in a first, uncompressed position with adjacent windingsspaced from one another.

When the device 10 has been positioned proximate the target region 90,the device 10 may be expelled from the distal holding section 136, asshown in FIG. 5B. For example, the device 10 may be rotated with thepush member 138 such that the anchoring member 18 screws into the targetregion 90 of cardiac tissue. As the anchoring member 18 is screwed intothe target region 90, the distal end of the open wound coil 132 mayengage the target tissue 90. Further rotation or screwing of theanchoring member into the target tissue 90 may cause the open wound coil132 to compress from the first position, shown in FIG. 5A to a second,compressed position, shown in FIG. 5B. In some instances, the open woundcoil 132 may be wound in an opposite direction than the helical tissueanchoring member 18 such that rotation of the device 10 with the distalend of the open wound coil 132 against the cardiac tissue 90 will notcause the open wound coil 132 to penetrate into the cardiac tissue 90,but rather remain against the surface of the cardiac tissue 90. As thedistal end of the coil 132 moves proximally relative to the housing 12(e.g., compresses) via engagement with the cardiac tissue 90, thespacing between adjacent windings of the open wound coil 132 will bereduced. Visual observation of the movement of the radiopaque material,such as the compression of the open wound coil 132, and thus thediminution of the spacing between adjacent windings, may provideintraoperative visual feedback via fluoroscopy during implantation ofanchoring member 18 of the device 10 into the target region 90. Forexample, medical personnel may confirm that the tissue anchoring member18 is sufficiently anchored in the cardiac tissue 90 when the open woundcoil 132 is compressed a predetermined amount and/or the distal end ofthe open wound coil 132 moves proximally relative to the housing 12 apredetermined amount at the second position.

FIGS. 6A and 6B illustrate another illustrative example of a tissueengagement verification feature 250 incorporated with the implantableleadless cardiac pacing device 10. Tissue engagement verificationfeatures 250 may be fixedly attached to the housing 12 of the device 10.In other words, the tissue engagement verification features 250 may bedesigned so that during typical use, the tissue engagement verificationfeatures 250 remain attached to housing 12. In some embodiments, thetissue engagement verification features 250 may have some freedom ofmovement relative to the housing 10. For example, the tissue engagementverification features 250 may be capable of pivoting, rotating, orotherwise moving relative to housing 12.

The form of the tissue engagement verification features 250 may vary.For example, the tissue engagement verification features 250 may takethe form of a compressible member, such as one or more, or a pluralityof deflectable struts 232. The annular ring 240 is shown coaxial withthe helical tissue anchoring member 18, with the annular ring 240surrounding the tissue anchoring member 18. However, in otherembodiments, the annular ring 240 may be positioned within the helicaltissue anchoring member 18, or otherwise disposed. The struts 232 mayextend distally from the distal end of the housing 12, for example. Thestruts 232 may have a proximal end secured to the housing 12 and adistal end secured to the annular ring 240, for example.

The struts 232 may be configured to deflect, bend, collapse, orotherwise be altered to move the ends of the struts toward one another,when subjected to an external force. The struts 232 may be formed of aflexible material. For example, the struts 232 may be made from a metal,metal alloy, polymer (some examples of which are disclosed below), ametal-polymer composite, combinations thereof, and the like, or othersuitable material. Some examples of suitable metals and metal alloysinclude stainless steel, such as 304V, 304L, and 316LV stainless steel,a nickel-titanium alloy such as linear-elastic and/or super-elasticnitinol, other nickel alloys. Some examples of suitable polymers mayinclude elastomeric polyamides, polyurethane, polyether block amide(PEBA, for example available under the trade name PEBAX®), ethylenevinyl acetate copolymers (EVA), silicones, polyethylene (PE), as well asother suitable materials, or mixtures, combinations, copolymers thereof,and the like.

The tissue engagement verification feature 250 may be constructed suchthat the distal ends of the struts 232 and/or the annular ring 240 ispositioned a first distance from the distal end of the housing 12 whenin a first, uncompressed position, and the distal ends of the struts 232and/or the annular ring 240 is positioned a second distance (e.g., asecond, compressed position), less than the first distance (e.g., movedproximally toward the distal end of the housing 12), with an appliedforce, such as upon engagement of the distal ends of the struts 232and/or the annular ring 240 with cardiac tissue.

The struts 232 and/or the annular ring 240 may be doped with, made of,or otherwise include a radiopaque material, and thus serve as aradiopaque marker. For example, the annular ring 240 may be formed of aradiopaque material or be doped with a radiopaque material, and thusserve as a radiopaque marker. Radiopaque materials are understood to bematerials capable of producing a relatively bright image on afluoroscopy screen or another imaging technique during a medicalprocedure. This relatively bright image aids the user of the device 10visualizing the radiopaque annular ring 240 using fluoroscopy. Someexamples of radiopaque materials can include, but are not limited to,gold, platinum, palladium, tantalum, tungsten alloy, polymer materialloaded with a radiopaque filler, and the like.

In some instances, the device 10 may also include a radiopaque referencepoint which is stationary relative to the housing 12, or be included aspart of the housing 12. For example the radiopaque reference point 60may be a radiopaque ring surrounding the housing 12, or anotherradiopaque structure on the housing 12, or the material forming thehousing 12. Accordingly, displacement of the radiopaque material of thestruts 232 and/or the annular ring 240 relative to the radiopaquereference point 60 may provide visual feedback of engagement of thetissue anchoring member 18 in cardiac tissue.

FIGS. 7A and 7B illustrate aspects of an exemplary method of implantingthe leadless pacing device shown in FIGS. 6A and 6B into cardiac tissueusing the delivery catheter 100. The delivery catheter 100, previouslydescribed above, may include a distal member or holding section 136configured to house the implantable device 10 during a deliveryprocedure. Additional features of the delivery catheter 100 have beendescribed above.

The catheter 100 may be advanced through the vasculature to targetregion 90, with the device 10 positioned in the distal holding section136 of the delivery catheter 100. For example, the catheter 100 may beadvanced through a femoral vein, into the inferior vena cava, into theright atrium, through the tricuspid valve, and into the right ventricle.The target region 90 may be a portion of the right ventricle. Forexample, the target region 90 may be a portion of the right ventriclenear the apex of the heart. In other instances, however, the targetregion 90 may be in another portion of the heart, such as in anotherchamber of the heart, for example.

The device 10 may include the anchor member 18 and tissue engagementverification features, such as the tissue engagement verificationfeature 250 including the struts 232 and/or annular ring 240. Duringadvancement of the catheter 100 through the vasculature, the struts 232,which may extend distally from the distal end of the housing 12, may bein a first, uncompressed position positioning the distal ends of thestruts 232 and/or annular ring 240 a first distance from the distal endof the housing 12.

When the device 10 has been positioned proximate the target region 90,the device 10 may be expelled from the distal holding section 136, asshown in FIG. 7B. For example, the device 10 may be rotated with thepush member 138 such that the anchoring member 18 screws into the targetregion 90 of cardiac tissue. As the anchoring member 18 is screwed intothe target region 90, the distal end of the tissue engagementverification feature 250, such as the distal ends of the struts 232and/or the annular ring 240, may engage the target tissue 90. Furtherrotation or screwing of the anchoring member into the target tissue 90may cause the struts 232 to deflect, bend, collapse or otherwise bealtered from the first position, shown in FIG. 7A to a second,compressed position, shown in FIG. 7B. As the distal ends of the struts232 move proximally relative to the housing 12 (e.g., compress) viaengagement with the cardiac tissue 90, the annular ring 240 will movecloser to the distal end of the housing 12. Visual observation of themovement of the radiopaque material, such as the distal ends of thestruts 232 and/or the annular ring 240, in relation to the radiopaquereference point (e.g., the housing 12 or a marker on the housing 12),may provide intraoperative visual feedback via fluoroscopy duringimplantation of anchoring member 18 of the device 10 into the targetregion 90. For example, medical personnel may confirm that the tissueanchoring member 18 is sufficiently anchored in the cardiac tissue 90when the distal ends of the struts 232 and/or the annular ring 240 moveproximally a predetermined amount to the second position, such that thedistal ends of the struts 232 and/or the annular ring 240 are positioneda predetermined distance from the distal end of the housing 12.

FIG. 8 illustrates another illustrative example of a tissue engagementverification feature 350 incorporated with the implantable leadlesscardiac pacing device 10, such as incorporated with the helicalanchoring member 18. The form of the tissue engagement verificationfeature 350 may vary. For example, the tissue engagement verificationfeature 350 may take the form of a movable member, such as a bead 340slidably disposed on the helical anchoring member 18. The bead 340 isshown surrounding the helical tissue anchoring member 18. However, inother embodiments, the bead 340, or other movable member, may beotherwise slidably coupled to the helical tissue anchoring member 18, orotherwise disposed. In some instances, the helical tissue anchoringmember 18 may include a stop 342 located distal of the bead 340 toprevent disengagement of the bead 340 from the tissue anchoring member18. In some instances, the stop 342 may include an annular rim, a ridge,bump or other feature configured to contact the bead 340 at a distalmostend of travel of the bead 340 along the tissue anchoring member 18. Thebead 340 may be configured to travel proximally along the helicalanchoring member 18 from the distalmost end of travel defined by thestop 342.

The tissue engagement verification feature 350 may be constructed suchthat the bead 340 is positioned on the helical tissue anchoring member18 at a first distance from the distal end of the housing 12 when in afirst position, and the bead 340 is movable along the tissue anchoringstructure 18 such that the bead 340 is positioned a second distance lessthan the first distance in a second position, as the tissue engagementmember 18 is screwed into cardiac tissue.

The bead 340 may be doped with, made of, or otherwise include aradiopaque material, and thus serve as a radiopaque marker. For example,the bead 340 may be formed of a radiopaque material or be doped with aradiopaque material, and thus serve as a radiopaque marker. Radiopaquematerials are understood to be materials capable of producing arelatively bright image on a fluoroscopy screen or another imagingtechnique during a medical procedure. This relatively bright image aidsthe user of the device 10 visualizing the radiopaque bead 340 usingfluoroscopy. Some examples of radiopaque materials can include, but arenot limited to, gold, platinum, palladium, tantalum, tungsten alloy,polymer material loaded with a radiopaque filler, and the like.

In some instances, the device 10 may also include a radiopaque referencepoint which is stationary relative to the housing 12, or be included aspart of the housing 12. For example the radiopaque reference point 60may be a radiopaque ring surrounding the housing 12, or anotherradiopaque structure on the housing 12, or the material forming thehousing 12. Accordingly, displacement of the radiopaque bead 340relative to the radiopaque reference point 60 may provide visualfeedback of engagement of the tissue anchoring member 18 in cardiactissue.

FIGS. 9A and 9B illustrate aspects of an exemplary method of implantingthe leadless pacing device shown in FIG. 8 into cardiac tissue using thedelivery catheter 100. The delivery catheter 100, previously describedabove, may include a distal member or holding section 136 configured tohouse the implantable device 10 during a delivery procedure. Additionalfeatures of the delivery catheter 100 have been described above.

The catheter 100 may be advanced through the vasculature to targetregion 90, with the device 10 positioned in the distal holding section136 of the delivery catheter 100. For example, the catheter 100 may beadvanced through a femoral vein, into the inferior vena cava, into theright atrium, through the tricuspid valve, and into the right ventricle.The target region 90 may be a portion of the right ventricle. Forexample, the target region 90 may be a portion of the right ventriclenear the apex of the heart. In other instances, however, the targetregion 90 may be in another portion of the heart, such as in anotherchamber of the heart, for example.

The device 10 may include the anchor member 18 and tissue engagementverification features, such as the tissue engagement verificationfeature 350 including the bead 340 slidably coupled to the helicalanchoring member 18. During advancement of the catheter 100 through thevasculature, the bead 340, which may be positioned proximate the stop342, may be in a first position positioning the bead 340 a firstdistance from the distal end of the housing 12.

When the device 10 has been positioned proximate the target region 90,the device 10 may be expelled from the distal holding section 136, asshown in FIG. 7B. For example, the device 10 may be rotated with thepush member 138 such that the anchoring member 18 screws into the targetregion 90 of cardiac tissue. As the anchoring member 18 is screwed intothe target region 90, the bead 340 may engage the target tissue 90, andslide along the anchoring member 18. Further rotation or screwing of theanchoring member into the target tissue 90 may cause the bead 340 tomove along the anchoring member 18 from the first position, shown inFIG. 9A to a second position, shown in FIG. 9B. As the anchoring member18 is screwed into the target tissue 90, the bead 340 moves proximallyrelative to the housing 12 along the anchoring member 18 via engagementwith the cardiac tissue 90. Visual observation of the movement of theradiopaque material, such as the bead 340, in relation to the radiopaquereference point (e.g., the housing 12 or a marker 60 on the housing 12),may provide intraoperative visual feedback via fluoroscopy duringimplantation of anchoring member 18 of the device 10 into the targetregion 90. For example, medical personnel may confirm that the tissueanchoring member 18 is sufficiently anchored in the cardiac tissue 90when the bead 340 moves proximally a predetermined amount to the secondposition, such that the bead 340 is positioned a predetermined distancefrom the distal end of the housing 12.

It should be understood that this disclosure is, in many respects, onlyillustrative. Changes may be made in details, particularly in matters ofshape, size, and arrangement of steps without exceeding the scope of thedisclosure. This may include, to the extent that it is appropriate, theuse of any of the features of one example embodiment being used in otherembodiments. The invention's scope is, of course, defined in thelanguage in which the appended claims are expressed.

Additional Examples

A first example is an implantable leadless cardiac pacing deviceincluding a housing having a proximal end and a distal end, an electrodepositioned proximate the distal end of the housing configured to bepositioned adjacent cardiac tissue, and a tissue anchoring memberextending from the distal end of the housing configured to secure thehousing to cardiac tissue. The device further includes a tissueengagement verification feature configured to provide feedback uponengagement of the tissue anchoring member in cardiac tissue.

Additionally or alternatively, in a second example, the tissueengagement verification feature is movable from a first positionrelative to the housing to a second position relative to the housing.

Additionally or alternatively, in a third example, the first position isan equilibrium position, and the second position is a displaced positionthrough application of an external force.

Additionally or alternatively, in a fourth example, the tissueengagement verification feature moves toward the proximal end of thehousing as the tissue engagement verification feature moves from thefirst position to the second position.

Additionally or alternatively, in a fifth example, the tissue engagementverification feature includes a radiopaque material to provide visualfeedback via fluoroscopy.

Additionally or alternatively, in a sixth example, the radiopaquematerial is movable relative to the housing.

Additionally or alternatively, a seventh example includes radiopaquereference point which is stationary relative to the housing, whereindisplacement of the radiopaque material relative to the radiopaquereference point provides visual feedback of engagement of the tissueanchoring member in cardiac tissue.

Additionally or alternatively, in an eighth example, the tissueengagement verification feature includes one or more tines configured todeflect upon engagement with cardiac tissue.

Additionally or alternatively, in a ninth example, the tissue engagementverification feature includes a compressible member configured tocompress upon engagement with cardiac tissue.

Additionally or alternatively, in a tenth example, the compressiblemember includes an open wound coil.

Additionally or alternatively, in an eleventh example, adjacent windingsof the open wound coil move closer together upon engagement of the openwound coil with cardiac tissue.

Additionally or alternatively, in a twelfth example, the compressiblemember includes one or more deflectable struts.

Additionally or alternatively, in a thirteenth example, the one or moredeflectable struts extend between the distal end of the housing to aring comprising a radiopaque material.

Additionally or alternatively, in a fourteenth example, the tissueengagement verification feature includes a radiopaque member configuredto move along the tissue anchoring member upon engagement with cardiactissue.

Additionally or alternatively, in a fifteenth example, the radiopaquemember includes a bead slidable along tissue anchoring member.

What is claimed is:
 1. An implantable leadless cardiac pacemakercomprising: a housing having a proximal end and a distal end anddefining an axis therebetween; a first electrode positioned proximatethe distal end of the housing, the first electrode configured andadapted to be positioned against and in electrical contact with cardiactissue; a second electrode located on the housing and electricallyisolated from the first electrode; a helical tissue anchor extendingfrom the distal end of the housing, the helical tissue anchor configuredand adapted to be inserted into the cardiac tissue to secure the housingto the cardiac tissue; and a tissue engagement member surrounding thehelical tissue anchor, the tissue engagement member being axiallycompressible from an axially extended configuration to an axiallycontracted configuration upon engagement with the cardiac tissue,wherein a distal end of the tissue engagement member is movable relativeto the helical tissue anchor and the housing as the tissue engagementmember is axially compressed from the axially extended configuration tothe axially contracted configuration.
 2. The implantable leadlesscardiac pacemaker of claim 1, wherein the tissue engagement memberincludes an annular ring at the distal end thereof.
 3. The implantableleadless cardiac pacemaker of claim 2, wherein the tissue engagementmember includes one or deflectable struts extending proximally from theannular ring.
 4. The implantable leadless cardiac pacemaker of claim 2,wherein the annular ring includes a radiopaque material providing visualindication via fluoroscopy whether the tissue engagement member is inthe axially extended configuration or the axially contractedconfiguration.
 5. The implantable leadless cardiac pacemaker of claim 1,wherein the axially extended configuration of the tissue engagementmember is an equilibrium position.
 6. The implantable leadless cardiacpacemaker of claim 1, wherein the tissue engagement member is disposedcoaxially around the helical tissue anchor.
 7. The implantable leadlesscardiac pacemaker of claim 1, wherein the helical tissue anchorsurrounds the first electrode.
 8. The implantable leadless cardiacpacemaker of claim 3, wherein the helical tissue anchor extends distallybeyond the tissue engagement member in the axially contractedconfiguration.
 9. An implantable leadless cardiac pacemaker comprising:a housing having a proximal end and a distal end and defining an axistherebetween; a first electrode positioned proximate the distal end ofthe housing, the first electrode configured and adapted to be positionedagainst and in electrical contact with cardiac tissue; a secondelectrode located on the housing and electrically isolated from thefirst electrode; a helical tissue anchor extending from the distal endof the housing, the helical tissue anchor configured and adapted to bescrewed into the cardiac tissue to secure the housing to the cardiactissue; and a tissue engagement member surrounding the helical tissueanchor, the tissue engagement member having a proximal end secured tothe housing and an opposite distal end; wherein the distal end of thetissue engagement member is configured to engage the cardiac tissue asthe helical tissue anchor is screwed into the cardiac tissue;
 10. Theimplantable leadless cardiac pacemaker of claim 9, wherein the distalend of the tissue engagement member is axially displaceable relative tothe helical tissue anchor and the housing.
 11. The implantable leadlesscardiac pacemaker of claim 10, wherein the distal end of the tissueengagement member is axially movable from an axially extendedconfiguration in which the distal end of the tissue engagement member ispositioned a first axial distance from the distal end of the housing toan axially contracted configuration in which the distal end of thetissue engagement member is positioned a second axial distance from thedistal end of the housing, the second axial distance being less than thefirst axial distance.
 12. The implantable leadless cardiac pacemaker ofclaim 11, wherein the axially extended configuration is an equilibriumposition of the tissue engagement member.
 13. The implantable leadlesscardiac pacemaker of claim 9, wherein the tissue engagement membercoaxially surrounds the helical tissue anchor.
 14. The implantableleadless cardiac pacemaker of claim 9, wherein the helical tissue anchorsurrounds the first electrode.
 15. The implantable leadless cardiacpacemaker of claim 9, wherein the distal end of the tissue engagementmember is configured to press against the cardiac tissue when thehelical tissue anchor is screwed into the cardiac tissue.
 16. Theimplantable leadless cardiac pacemaker of claim 9, wherein the tissueengagement member includes an annular ring at the distal end thereof.17. The implantable leadless cardiac pacemaker of claim 16, wherein thetissue engagement member includes one or deflectable struts extendingproximally from the annular ring.
 18. The implantable leadless cardiacpacemaker of claim 16, wherein the annular ring includes a radiopaquematerial providing visual indication via fluoroscopy whether the tissueengagement member is in engagement with the cardiac tissue.
 19. A methodof implanting a leadless cardiac pacemaker, the method comprising:advancing a leadless cardiac pacemaker into a chamber of a heart whilecontained within the distal end of a delivery catheter, the leadlesscardiac pacemaker including a housing having a distal end and a proximalend; screwing a helical tissue anchor extending from the distal end ofthe housing into cardiac tissue to secure the leadless cardiac pacemakerto the cardiac tissue; axially compressing a tissue engagement member ofthe leadless cardiac pacemaker from an axially extended configuration toan axially contracted configuration via engagement of a distal end ofthe tissue engagement member with the cardiac tissue as the helicaltissue anchor is being screwed into the cardiac tissue; and removing thedelivery catheter from the chamber of the heart.
 20. The method of claim19, wherein the tissue engagement member surrounds the helical tissueanchor.